Literature DB >> 11359126

Classification of cilio-inhibiting effects of nasal drugs.

P Merkus1, S G Romeijn, J C Verhoef, F W Merkus, P F Schouwenburg.   

Abstract

OBJECTIVE/HYPOTHESIS: Nasal drug formulations are widely used for a local therapeutic effect, but are also used for systemic drug delivery. In the development of new nasal drugs, the toxic effects on the mucociliary clearance and therefore on the ciliated tissue is of importance. In this study, the effect of nasal drugs and their excipients on the ciliary beat frequency (CBF) is investigated. STUDY
DESIGN: Experimental, in vitro.
METHODS: CBF is measured by a photograph-electric registration method. Excised ciliated chicken trachea tissue is incubated for 15 minutes in the formulation, followed by a reversibility test. To estimate the ciliostatic potential, a classification is given of all tested formulations. According to the CBF, after 60 minutes every drug or excipient could be classified as follows: cilio-friendly: after 60 minutes the CBF has regained 75% or more of its initial frequency; cilio-inhibiting: after 60 minutes the CBF has regained between 25% and 75% of its initial frequency; or ciliostatic: after 60 minutes the CBF has regained 25% or less of its initial frequency.
RESULTS: Most formulations used are cilio-friendly or cilio-inhibiting. Only some are ciliostatic. Preservatives have a major role in the cilio-inhibiting effect of the drug. Also, other additives can contribute to the toxicity profile of nasal drug formulations.
CONCLUSION: This classification of the cilio-inhibiting potential of nasal drug formulations is a valuable tool in the design of safe nasal drugs. The number of animal studies in vivo can be reduced substantially by using this in vitro screening technique. This study demonstrates that the effect on ciliary movement of most drug formulations is due to the preservatives and/or additives and mostly not to the drug itself.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359126     DOI: 10.1097/00005537-200104000-00008

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  [Complications and side effects of conservative treatment of rhinological diseases].

Authors:  I Küster; C Rudack; A Beule
Journal:  HNO       Date:  2018-06       Impact factor: 1.284

3.  Embryonic chicken trachea as a new in vitro model for the investigation of mucociliary particle clearance in the airways.

Authors:  A Henning; M Schneider; M Bur; F Blank; P Gehr; C-M Lehr
Journal:  AAPS PharmSciTech       Date:  2008-04-02       Impact factor: 3.246

4.  CiliarMove: new software for evaluating ciliary beat frequency helps find novel mutations by a Portuguese multidisciplinary team on primary ciliary dyskinesia.

Authors:  Pedro Sampaio; Mónica Ferro da Silva; Inês Vale; Mónica Roxo-Rosa; Andreia Pinto; Carolina Constant; Luisa Pereira; Carla M Quintão; Susana S Lopes
Journal:  ERJ Open Res       Date:  2021-02-08

Review 5.  Airway Epithelial Cell Cilia and Obstructive Lung Disease.

Authors:  Asma Yaghi; Myrna B Dolovich
Journal:  Cells       Date:  2016-11-11       Impact factor: 6.600

Review 6.  Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors.

Authors:  Marta Joskova; Juraj Mokry; Sona Franova
Journal:  Front Pharmacol       Date:  2020-05-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.